On examination, body temperature was 38.2c, oropharynx was hyperemic and bilateral crackles were detected by lung auscultation. She was diagnosed with viral upper respiratory tract infection in another hospital. CasePresentation: A 13 months-old girl was admitted to emergency department with a 10-day history of cough, which was gradually progressive.
Here, we report a clinical case of an infant with severe pertussis with vaccinerefusing parents. The concept of increasing vaccine refusal has emerged in the world in the 1990s and in Turkey in the beginning of 2010. In recent years, the number of parents refusing recommended childhood vaccination increased significantly. © 2016 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).Vaccines are the most effective public health interventions against manyvaccine-preventable diseases. There was no hypercalcaemia documented with single bolus dosing in this study.Ģ5OHD cholecalciferol infant newborn vitamin D. Single bolus dosing of 50 000 IU cholecalciferol achieves higher 25OHD repletion rates at 1-2 weeks of age compared with daily dosing, but repletion rates were similar by 3-4 months. Mean adjusted total serum calcium in the bolus group were normal at 1-2 weeks (2.73 mmol/L) and 3-4 months (2.55 mmol/L). By 3-4 months, both groups achieved similar vitamin D repletion rates (91 vs. More infants in the single bolus group achieved vitamin D repletion (100 vs. This was reversed at 3-4 months, (65 nmol/L, 95% CI 59-71) compared with the daily group (81 nmol/L, 95% CI 77-85).
Mean 25OHD in the bolus group (154 nmol/L, 95% confidence interval (CI) 131-177) was higher than the daily group (48 nmol/L, 95% CI 42-54) at 1-2 weeks of age. Of 70 eligible infants, 36 received a daily dose and 34 received a single high-dose cholecalciferol. The secondary objective was determining safety using adjusted total serum calcium. The primary outcome measure was the rate of 25 hydroxyvitamin D (25OHD) repletion-defined as 25OHD greater than 50 nmol/L. It compared the efficacy and safety of daily (400 IU) versus a bolus dose (50 000 IU) of cholecalciferol in newborn infants of vitamin D deficient mothers. This single centre, open randomised controlled trial was conducted from August 2013 to May 2014. The study sought to evaluate this alternative approach of supplementation. There are no published data to demonstrate the efficacy of bolus dose vitamin D in newborn infants.
0 kommentar(er)
